Skip to main content
DIACEUTICS PLC logo

DIACEUTICS PLC — Investor Relations & Filings

Ticker · DXRX ISIN · GB00BJQTGV64 LEI · 213800VEWQBB39ZB8J81 IL Telecommunications, computer programming, consultancy, computing infrastructure, and other information service activities
Open in API
Filings indexed 277 across all filing types
Latest filing 2025-09-09 Major Shareholding Noti…
Country GB United Kingdom
Listing IL DXRX

About DIACEUTICS PLC

https://www.diaceutics.com/

Diaceutics PLC is a data analytics and end-to-end services provider focused on the development and commercialization of precision medicine diagnostics. The company supports pharmaceutical and biotech clients by providing solutions to improve the diagnostic testing ecosystem, aiming to ensure patients receive the correct personalized treatment. Its primary offering is DXRX, The Diagnostic Network®, a diagnostic commercialization platform for precision medicine. DXRX facilitates collaboration among stakeholders, including laboratories and pharmaceutical companies, in a secure marketplace and provides access to real-world diagnostic testing data. This integrated platform is designed to streamline the launch and adoption of new precision medicines.

Recent filings

Filing Released Lang Actions
Holding(s) in Company
Major Shareholding Notification Classification · 100% confidence The document is a 'TR-1: Standard form for notification of major holdings'. It explicitly details a change in share ownership (from 16.29% to 17.02%) by Gresham House Asset Management Ltd in Diaceutics PLC. This is a standard regulatory disclosure for major shareholding notifications, which corresponds to the 'Major Shareholding Notification' category.
2025-09-09 English
PDMR Shareholding/Share Incentive Plan and TVR
Director's Dealing Classification · 100% confidence The document is a formal notification of share transactions by Persons Discharging Managerial Responsibilities (PDMRs) at Diaceutics PLC. It explicitly includes the required 'Notification of a Transaction' tables pursuant to Article 19(1) of the EU Market Abuse Regulation (MAR). This aligns perfectly with the definition of a Director's Dealing (DIRS) filing, which covers personal share transactions by company executives.
2025-09-02 English
Holding(s) in Company
Major Shareholding Notification Classification · 100% confidence The document is a 'TR-1: Standard form for notification of major holdings'. It explicitly details a change in share ownership (from 15.62% to 16.29%) by Gresham House Asset Management Ltd in Diaceutics PLC. This is a classic regulatory disclosure regarding significant shareholding thresholds, which falls under the 'Major Shareholding Notification' category.
2025-08-11 English
Diaceutics at Canaccord Genuity Growth Conference
Regulatory Filings Classification · 100% confidence The document is a short press release (Reach announcement) informing the public that Diaceutics PLC management will be attending and presenting at the Canaccord Genuity 45th Annual Growth Conference. It does not contain the actual presentation slides or financial data, nor does it fit into specific categories like earnings releases or regulatory filings. As it is a general corporate announcement regarding an upcoming event, it falls under the 'Regulatory Filings' (RNS) category as a miscellaneous corporate communication.
2025-08-05 English
PDMR Shareholding/Share Incentive Plan and TVR
Director's Dealing Classification · 100% confidence The document is a formal notification of share transactions by Persons Discharging Managerial Responsibilities (PDMRs) at Diaceutics PLC. It explicitly includes the required regulatory disclosures under Article 19(1) of the EU Market Abuse Regulation (MAR) for multiple executives (Susanne Munksted, Jordan Clark, Nick Roberts, and Jillian Beggs). Since the document reports personal share transactions by company directors and executives, it falls under the 'Director's Dealing' category.
2025-07-30 English
Diaceutics Announces Key Leadership Appointment
Board/Management Information Classification · 100% confidence The document is a press release announcing the appointment of a new General Counsel and Group Company Secretary at Diaceutics PLC. This falls under the category of board or management changes, which is explicitly defined as 'MANG'.
2025-07-29 English

Browse filings by year

21 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.